Visfatin and oxidative stress influence endothelial progenitor cells in obese populations

Endocrine Research

Volumn 40, Issue 2, 2015, Pages 83-87

  Chen, Shuchun ^a,b   Sun, Lina ^c   Gao, Haina ^c   Ren, Luping ^a,b   Liu, Na ^a,b   Song, Guangyao ^a,b  

^a Hebei Research Institute for Endocrine and Metabolic Diseases   (China)

^b HEBEI GENERAL HOSPITAL   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Endothelial progenitor cells; Obesity; Oxidative stress; Visfatin

Indexed keywords

ANTIOXIDANT; CD309 ANTIGEN; CD34 ANTIGEN; GLUCOSE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; INSULIN; LYMPHOCYTE ANTIGEN; MALONALDEHYDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; OBESITY; OXIDATIVE STRESS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTIOXIDANTS; BODY MASS INDEX; CASE-CONTROL STUDIES; CYTOKINES; ENDOTHELIAL PROGENITOR CELLS; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE;

EID: 84929306042     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2014.952016     Document Type: Article

References (32)

1. Shea J, Diamandis EP, Sharma AM, et al. The obesity epidemic. Clin Chem 2012;58:968-73
2. Berrington De Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. New Engl J Med 2010;363:2211-19
3. Logue J, Murray HM, Welsh P, et al. Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart 2011;97:564-8
4. Van Guilder GP, Hoetzer GL, Dengel DR, et al. Impaired endothelium-dependent vasodilation in normotensive and normoglycemic obese adult humans. J Cardiovasc Pharmacol 2006;47: 310-13
5. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008;10: 1713-65
6. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-53
7. Bakogiannis C, Tousoulis D, Androulakis E, et al. Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes. Curr Med Chem 2012;19:2597-604
8. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005;111:2981-7
9. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999-1007
10. Mikirova NA, Casciari JJ, Hunninghake RE, Beezley MM. Effect of weight reduction on cardiovascular risk factors and CD34-positive cells in circulation. Int J Med Sci 2011;8:445-52
11. Boini KM, Zhang C, Xia M, et al. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta 2010;1801:1294-304
12. Chang YH, Chang DM, Lin KC, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515-27
13. Sun Y, Chen S, Song G, et al. Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action. Int J Mol Med 2012;30:622-8
14. Fadini GP, Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab 2010;12:570-83
15. La Vignera S, Condorelli R, Vicari E, et al. Circulating endothelial progenitor cells and endothelial microparticles in patients with arterial erectile dysfunction and metabolic syndrome. J Androl 2012;33:202-9
16. Tobler K, Freudenthaler A, Baumgartner-Parzer SM, et al. Reduction of both number and proliferative activity of human endothelial progenitor cells in obesity. Int J Obes (Lond) 2010;34: 687-700
17. Chan RS, Woo J. Prevention of overweight and obesity: how effective is the current public health approach. Int J Environ Res Public Health 2010;7:765-83
18. Duvnjak M, Lerotic I, Barsic N, et al. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007;13:4539-50
19. Khan NI, Naz L, Yasmeen G. Obesity: an independent risk factor for systemic oxidative stress. Pak J Pharm Sci 2006;19:62-5
20. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011;12: 3117-32
21. Kaminska A, Kopczynska E, Bronisz A, et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010;61:169-73
22. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 2012;32:229-43
23. Esteghamati A, Morteza A, Zandieh A, et al. The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis. J Cardiovasc Transl Res 2012;5:541-6
24. Kowalska I, Karczewska-Kupczewska M, Adamska A, et al. Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men. J Clin Endocrinol Metab 2013;98:E293-7
25. Mu J, Feng B, Ye Z, et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011;24:177-84
26. Filippatos TD, Tsimihodimos V, Derdemezis CS, et al. Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr Metab Cardiovasc Dis 2013;23:330-6
27. Buldak RJ, Polaniak R, Buldak L, et al. Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma ME45 cells. J Physiol Pharmacol 2013;64:377-85
28. Adams Jr JD, Alzheimer's disease, ceramide, visfatin and NAD. CNS Neurol Disord Drug Targets 2008;7:492-8
29. Lim SY, Davidson SM, Paramanathan AJ, et al. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008;12:1395-403
30. Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356-65
31. Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007;357:150-6
32. Lee WJ, Wu CS, Lin H, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond) 2009;33:465-72